Որոնման արդյունքները - Do‐Youn Oh
- Ցուցադրվում են 1 - 20 արդյունքները 109
- Գնացեք Հաջորդ էջ
-
1
Recent Progress in Immunotherapy for Gastric Cancer Jeesun Yoon, Tae‐Yong Kim, Do‐Youn Oh
Հրապարակվել է 2023Revisão -
2
-
3
Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer Sun Kyung Baek, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Հրապարակվել է 2011Artigo -
4
-
5
-
6
Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study Makoto Ueno, Hyun Cheol Chung, Adnan Nagrial, Aurélien Marabelle, Robin Kate Kelley, Lu Xu, Janine Mahoney, Scott K. Pruitt, Do‐Youn Oh
Հրապարակվել է 2018Artigo -
7
-
8
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, Do‐Youn Oh, John Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Հրապարակվել է 2024Artigo -
9
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index Younak Choi, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Հրապարակվել է 2015Artigo -
10
The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy Younak Choi, Tae-Yong Kim, Do‐Youn Oh, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Հրապարակվել է 2015Artigo -
11
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Hyung-Seok Hur, Do Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Tae‐You Kim
Հրապարակվել է 2009Artigo -
12
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Christoph Helwig, Isabelle Dussault, Masafumi Ikeda
Հրապարակվել է 2020Artigo -
13
Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer Chan‐Young Ock, Do‐Youn Oh, Joongyub Lee, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Հրապարակվել է 2015Artigo -
14
Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer Hae Young Chung, Yun Sok Lee, Rafael Mayoral, Do‐Youn Oh, Jenny Siu, Nicholas J. G. Webster, Dorothy D. Sears, Jerrold M. Olefsky, Lesley G. Ellies
Հրապարակվել է 2014Artigo -
15
Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract... Kyoung-Min Cho, Hyunkyung Park, Do‐Youn Oh, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Հրապարակվել է 2016Artigo -
16
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review Li‐Tzong Chen, Do‐Youn Oh, Min‐Hee Ryu, Kun‐Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jong-Seok Kim, Mauro Orlando, Yoon‐Koo Kang
Հրապարակվել է 2017Revisão -
17
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer Jiyoung Rhee, Sae‐Won Han, Do‐Youn Oh, Jee Hyun Kim, Seock‐Ah Im, Wonshik Han, In Ae Park, Dong‐Young Noh, Yung‐Jue Bang, Tae‐You Kim
Հրապարակվել է 2008Artigo -
18
Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas Do‐Youn Oh, Tae‐Won Kim, Young Suk Park, Sang Joon Shin, Seong Hoon Shin, Eun‐Kee Song, Hyo Jin Lee, Kewn‐wook Lee, Yung‐Jue Bang
Հրապարակվել է 2012Artigo -
19
Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab Hye Jung Chang, Sae‐Won Han, Do‐Youn Oh, S.-A. Im, Yoon Kyung Jeon, I. A. Park, Wenfei Han, Do Young Noh, Yung‐Jue Bang, T.-Y. Kim
Հրապարակվել է 2011Artigo -
20
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors Do‐Youn Oh, Se‐Hoon Lee, Sae‐Won Han, Mi‐Jung Kim, Tae-Min Kim, Tae‐You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung‐Jue Bang
Հրապարակվել է 2015Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Medicine
Internal medicine
Cancer
Oncology
Gastroenterology
Chemotherapy
Breast cancer
Biology
Adverse effect
Clinical endpoint
Cancer research
Immunotherapy
Surgery
Clinical trial
Pathology
Biochemistry
Confidence interval
Gene
Trastuzumab
Alternative medicine
Gemcitabine
Genetics
Placebo
Colorectal cancer
Hazard ratio
Surgical oncology
Pancreatic cancer
Pembrolizumab
Phases of clinical research
Receptor